Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -8.59 | -1.39 | -0.08 | 0.50 |
| FCF Yield | 3.10% | 2.92% | 3.09% | 2.97% |
| EV / EBITDA | 29.52 | 39.44 | 15.56 | 189.81 |
| Quality | ||||
| ROIC | 0.20% | 0.46% | 0.73% | -0.02% |
| Gross Margin | 55.61% | 57.01% | 59.75% | 56.29% |
| Cash Conversion Ratio | 7.38 | 4.72 | 3.19 | -7.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.15% | 6.32% | 4.95% | 2.24% |
| Free Cash Flow Growth | 45.38% | 4.85% | 3.51% | 7.54% |
| Safety | ||||
| Net Debt / EBITDA | -15.66 | -34.87 | -18.22 | -241.08 |
| Interest Coverage | 31.26 | 117.53 | 193.04 | -4.82 |
| Efficiency | ||||
| Inventory Turnover | 0.58 | 0.56 | 0.56 | 0.60 |
| Cash Conversion Cycle | 200.42 | 202.18 | 185.23 | 170.64 |